Literature DB >> 15215091

Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002.

Robert K Flamm1, Mellany K Weaver, Clyde Thornsberry, Mark E Jones, James A Karlowsky, Daniel F Sahm.   

Abstract

For the period from 1999 to 2002 in the United States, the in vitro susceptibilities of 52,637 Pseudomonas aeruginosa isolates to 10 antimicrobial agents were evaluated. The isolates were from 29 laboratories, 11 of which participated in The Surveillance Network for four consecutive years. Isolates were collected from adult patients (> or =18 years of age) in intensive care units (ICU), non-ICU inpatients, nursing home patients, and outpatients; data were analyzed to evaluate factors, such as year of isolation, patient age group, isolate specimen source, and patient type (hospitalized patients [ICU, non-ICU, or nursing home] or outpatients). Rates of resistance for the 4-year period were highest for isolates from patients in ICU and 18- to 39-year-old patients and for isolates from the lower respiratory tract. Resistance decreased with age. Resistance was lowest in isolates from outpatients, in isolates from > or =70-year-old patients, and from specimens from the upper respiratory tract. Multidrug resistance (MDR) (resistance to three or more antimicrobial agents) accounted for 24.9% of all isolates. The MDR rate was highest in isolates from patients in nursing homes (29.9%) and ICU (29.5%).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215091      PMCID: PMC434174          DOI: 10.1128/AAC.48.7.2431-2436.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Of Pseudomonas, porins, pumps and carbapenems.

Authors:  D M Livermore
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

2.  Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa.

Authors:  Y Carmeli; N Troillet; A W Karchmer; M H Samore
Journal:  Arch Intern Med       Date:  1999-05-24

3.  Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  A C Gales; R N Jones; J Turnidge; R Rennie; R Ramphal
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

4.  Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush.

Authors:  J Y Fagon; J Chastre; Y Domart; J L Trouillet; C Gibert
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

5.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

6.  Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997.

Authors:  D J Diekema; M A Pfaller; R N Jones; G V Doern; P L Winokur; A C Gales; H S Sader; K Kugler; M Beach
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

7.  Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network.

Authors:  James A Karlowsky; Laurie J Kelly; Clyde Thornsberry; Mark E Jones; Alan T Evangelista; Ian A Critchley; Daniel F Sahm
Journal:  Int J Antimicrob Agents       Date:  2002-01       Impact factor: 5.283

8.  Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.

Authors:  D F Sahm; I A Critchley; L J Kelly; J A Karlowsky; D C Mayfield; C Thornsberry; Y R Mauriz; J Kahn
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

9.  Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA).

Authors:  M A Pfaller; R N Jones; D J Biedenbach
Journal:  Diagn Microbiol Infect Dis       Date:  2001-12       Impact factor: 2.803

10.  Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).

Authors:  M A Pfaller; R N Jones; G V Doern; K Kugler
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more
  30 in total

1.  Synergistic interactions of Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro wound model.

Authors:  Stephanie DeLeon; Allie Clinton; Haley Fowler; Jake Everett; Alexander R Horswill; Kendra P Rumbaugh
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

2.  Patterns of antimicrobial use among nursing home residents with advanced dementia.

Authors:  Erika D'Agata; Susan L Mitchell
Journal:  Arch Intern Med       Date:  2008-02-25

3.  In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.

Authors:  Catharine C Bulik; Henry Christensen; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

Review 4.  Hospital epidemiology and infection control in acute-care settings.

Authors:  Emily R M Sydnor; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Quinolone-resistant clinical strains of Pseudomonas aeruginosa isolated from University Hospital in Tunisia.

Authors:  Mouna Ben Nejma; Olfa Sioud; Maha Mastouri
Journal:  3 Biotech       Date:  2017-11-13       Impact factor: 2.406

6.  Activity of pyocin S2 against Pseudomonas aeruginosa biofilms.

Authors:  Karen Smith; Laura Martin; Angela Rinaldi; Ranjith Rajendran; Gordon Ramage; Daniel Walker
Journal:  Antimicrob Agents Chemother       Date:  2011-12-19       Impact factor: 5.191

7.  ESBL and MBL in Cefepime Resistant Pseudomonas aeruginosa: An Update from a Rural Area in Northern India.

Authors:  Aarti Kotwal; Debasis Biswas; Barnali Kakati; Malvika Singh
Journal:  J Clin Diagn Res       Date:  2016-04-01

8.  Gallium maltolate treatment eradicates Pseudomonas aeruginosa infection in thermally injured mice.

Authors:  Katrina DeLeon; Fredrik Balldin; Chase Watters; Abdul Hamood; John Griswold; Sunil Sreedharan; Kendra P Rumbaugh
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

9.  Targeting a bacterial stress response to enhance antibiotic action.

Authors:  Samuel Lee; Aaron Hinz; Elizabeth Bauerle; Angus Angermeyer; Katy Juhaszova; Yukihiro Kaneko; Pradeep K Singh; Colin Manoil
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

10.  Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa.

Authors:  Fabio Ferrari; Qin Lu; Cassio Girardi; Olivier Petitjean; Charles-Hugo Marquette; Frederic Wallet; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2009-08-04       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.